ArticleCancer chemotherapy and pharmacology2018

A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer.

Amita Patnaik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.